Bristol Myers Squibb Sotyktu gets European Commission nod for adults with plaque psoriasis Ruchika Sharma30 March 2023 1:24 PM ISTSotyktu is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small...
USFDA nod to citrate free high concentration formulation of biosimilar Hyrimoz injection: Sandoz Ruchika Sharma22 March 2023 1:45 PM ISTSandoz intends to launch the Hyrimoz citrate-free HCF in the US on July 1, 2023.
Takeda declares positive results in Phase 2b Study of TAK-279 in people with moderate-to-severe Plaque Psoriasis Ruchika Sharma20 March 2023 3:44 PM ISTPsoriasis is a chronic autoimmune disease in which the body's immune system causes skin cells to multiply too quickly.
Tapinarof cream shown to be beneficial in atopic dermatitis patients as young as 2 years old: ADORING 2 trial Dr. Kamal Kant Kohli17 March 2023 7:45 PM ISTUSA: Topical VTAMA (tapinarof) cream was shown to be safe and effective in pediatric subjects down to 2 years old and adult subjects with atopic...
Goselkumab therapy beneficial for patients with moderate to severe plaque psoriasis Aditi31 Jan 2023 9:45 AM ISTUSA: A research report of a real-world study published in Dermatology and Therapy has concluded that patients with moderate-to-severe plaque...
Sponsor should submit rescue management plan: CDSCO Panel Tells Sun Pharma Over Psoriasis Drug Tildrakizumab Susmita Roy18 Jan 2023 6:00 PM ISTNew Delhi: Granting the permission to conduct the proposed study of Tildrakizumab 100mg/ml, the Subject Expert Committee (SEC) functional under the...
Researchers develop promising drug delivery method that could replace injections with pills Dr. Kamal Kant Kohli9 Jan 2023 7:30 PM ISTFor some chronic conditions such as rheumatoid arthritis, treatment often involves lifelong injections. New delivery strategies that combine efficacy...
Mirikizumab efficacy to placebo for treating moderate-to-severe plaque psoriasis Medha Baranwal3 Jan 2023 8:00 PM ISTUSA: Interleukin (IL)-23 and IL-17 are known to play critical roles in the development of psoriatic disease, so therapies targeting these cytokines...
Palmoplantar Plaque Psoriasis associated with Diabetes, Hypertension, Obesity, and Metabolic Syndrome- IDOJ Study Dr Manoj Kumar Nayak2 Jan 2023 9:45 AM ISTPalmoplantar Plaque Psoriasis associated with Diabetes, Hypertension, Obesity, and Metabolic Syndrome- IDOJ Study Psoriasis is a T cell‑mediated...
Secukinumab Dose Tapering ensures increased effectiveness of plaque psoriasis treatment Dr. Kamal Kant Kohli21 Oct 2022 7:30 PM ISTCHINA: According to a research study published in the journal Dermatologic Therapy, tapering off secukinumab dosages for individuals with plaque...
Biocon Biologics collaborates with Yoshindo to commercialize bUstekinumab, bDenosumab in Japan Ruchika Sharma17 Oct 2022 2:30 PM ISTDenosumab, a biosimilar referencing Prolia, is a monoclonal antibody for the treatment of osteoporosis.
Tildrakizumab therapy proves beneficial for Plaque Psoriasis Dr. Kamal Kant Kohli3 Oct 2022 8:00 PM ISTITALY: Tildrakizumab was found to be beneficial for up to 36 weeks in treating moderate-to-severe plaque psoriasis, according to a new study published...
